Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D09JSM
|
||||
| Former ID |
DNCL002198
|
||||
| Drug Name |
IMC-3C5
|
||||
| Indication | Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] | Phase 1 | [1] | ||
| Target and Pathway | |||||
| Target(s) | Vascular endothelial growth factor receptor 3 | Target Info | Modulator | [2] | |
| KEGG Pathway | Ras signaling pathway | ||||
| Rap1 signaling pathway | |||||
| Cytokine-cytokine receptor interaction | |||||
| PI3K-Akt signaling pathway | |||||
| Focal adhesion | |||||
| NetPath Pathway | TNFalpha Signaling Pathway | ||||
| Pathway Interaction Database | VEGF and VEGFR signaling network | ||||
| VEGFR3 signaling in lymphatic endothelium | |||||
| Reactome | VEGF binds to VEGFR leading to receptor dimerization | ||||
| WikiPathways | Signaling by VEGF | ||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01288989) A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors. U.S. National Institutes of Health. | ||||
| REF 2 | Bevacizumab and breast cancer: what does the future hold?. Future Oncol. 2012 April; 8(4): 403-414. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.